Last 22 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 8.38 | — | 1.32 | — | — | — | — | — | 37.00 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 83.95 | 55.91 | 30.90 | 585.19 | 1082.38 | 65.81 | 24.94 | 21.50 | 22.78 | 60.03 | 79.76 | — | — |
| — | -15.0% | +23.9% | +2621.9% | +4650.9% | +9.6% | -68.7% | — | — | — | — | — | — | |
| P/B Ratio | 1.11 | 1.12 | 1.22 | 2.20 | 1.69 | 1.63 | 1.64 | 1.05 | 1.82 | 2.50 | 2.36 | — | — |
| — | -31.2% | -25.7% | +109.8% | -7.2% | -34.7% | -30.5% | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | 0.60 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
PureTech Health plc's operating margin was -2589.5% in Q2 2025, down 858.7 pp QoQ and down 171.6 pp YoY. The trailing four-quarter average of -16571.3% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 44172.3% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 26.0% | -1245.2% | 1066.7% | -13416.7% | -940.0% | 2.8% | -276.6% | -501.6% | -640.2% | -314.1% | -295.5% | -458.9% | -1095.7% |
| — | -44172.3% | +485.6% | -2575.0% | -46.8% | +100.9% | +6.4% | -9.3% | +41.6% | +25.0% | -64.2% | +19.2% | +40.1% | |
| Operating Margin | -2818.9% | -2589.5% | -1730.7% | -23054.9% | -38910.1% | -2417.8% | -1125.0% | -1439.4% | -711.6% | -1166.6% | -1355.6% | -771.2% | -1200.8% |
| — | -7.1% | -53.8% | -1501.6% | -5368.1% | -107.3% | +17.0% | -86.6% | +40.7% | +27.2% | -313.7% | +26.7% | +61.4% | |
| Net Margin | 1108.3% | -2409.8% | 2366.1% | -14504.5% | -22606.7% | -793.8% | -256.3% | -403.2% | 128.4% | -1291.9% | -2395.9% | 1811.2% | 7247.3% |
| — | -203.6% | +1023.2% | -3497.5% | -17701.5% | +38.6% | +89.3% | -122.3% | -98.2% | -300.0% | -939.8% | +1332.3% | +97.4% |
| Metric | TTM | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 12.4% | -11.5% | 26.7% | -10.9% | -8.3% | -4.7% | -4.1% | -4.9% | 2.6% | -12.4% | -16.3% | 17.5% | 92.8% |
| — | -142.6% | +749.3% | -123.7% | -419.3% | +61.9% | +74.8% | -127.9% | -97.2% | -182.0% | +13.8% | +436.0% | -34.7% | |
| ROA | 8.3% | -7.7% | 16.1% | -6.6% | -5.8% | -3.6% | -3.0% | -3.2% | 1.6% | -8.0% | -11.1% | 12.1% | 51.1% |
| — | -115.5% | +632.5% | -104.7% | -458.0% | +55.2% | +72.6% | -126.5% | -96.8% | -249.5% | -33.4% | +741.4% | +126.5% | |
| ROIC | -46.2% | -25.8% | -59.9% | -31.4% | -21.9% | -18.2% | -21.6% | -35.4% | -33.7% | -19.4% | -12.4% | -7.7% | -14.2% |
| — | -41.8% | -176.7% | +11.4% | +35.0% | +6.5% | -74.1% | -357.3% | -137.4% | +62.7% | +67.7% | +86.4% | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 16.1% YoY to 8.49x, strengthening the short-term liquidity position.
| Metric | TTM | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.06 | 0.05 | 0.09 | 0.06 | 0.05 | 0.09 | 0.08 | 0.09 | 0.14 | 0.12 | 0.05 | 0.06 |
| — | +12.8% | -36.0% | +6.7% | -37.9% | -63.6% | -27.0% | +66.5% | +47.4% | -55.6% | +58.3% | -12.5% | -48.1% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 9.33 | 8.49 | 9.33 | 3.68 | 6.76 | 7.31 | 3.99 | 2.54 | 2.22 | 2.11 | 2.29 | 2.22 | 1.21 |
| — | +16.1% | +134.1% | +44.8% | +204.6% | +246.7% | +74.1% | +14.3% | +82.9% | +204.9% | +134.3% | +128.9% | +67.7% | |
| Quick Ratio | 9.33 | 8.49 | 9.33 | 3.68 | 6.76 | 7.31 | 3.99 | 2.54 | 2.22 | 2.11 | 2.29 | 2.22 | 1.21 |
| — | +16.1% | +134.1% | +44.8% | +204.6% | +246.7% | +74.1% | +14.3% | +82.9% | +196.7% | +134.3% | +128.9% | +67.7% | |
| Interest Coverage | -13.56 | -50.24 | — | -5.84 | -8.24 | -15.27 | -48.52 | — | — | — | — | -291.61 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 22 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonPureTech Health plc's current P/E is 8.4x. The average P/E over the last 1 quarters is 1.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
PureTech Health plc's current operating margin is -2818.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking PureTech Health plc's business trajectory between earnings reports.